insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

RCOR · Renovacor, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21Q1 '21Q4 '20Q3 '20Q2 '20
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$7.42M$6.29M$5.93M-$892.0K-----
SG&A$4.68M$385.0K$526.0K-$147.0K-----
Total Operating Expenses-----$1.06M$871.1K-$492.8K$82.3K
D&A--$1.0K-------
Operating Income($12.11M)($9.13M)($8.86M)-($5.24M)($1.09M)($16.9K)-($492.8K)($82.3K)
Interest Expense$4.0K---$147.0K-----
Income Tax----------
Net Income($15.23M)($4.02M)$6.59M-($8.17M)($488.0K)($1.20M)-($484.8K)($70.8K)
EPS - Basic($0.87)($0.59)$0.37-------
EPS - Diluted($0.87)($0.59)$0.36-------

Balance Sheet

Line itemQ3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21Q1 '21Q4 '20Q3 '20Q2 '20
Cash & Equivalents$53.71M$61.99M$70.08M$78.79M$85.30M$304.6K$595.8K$687.3K$767.6K$1.03M
Accounts Receivable----------
Inventory----------
Accounts Payable$3.23M$1.55M$1.78M$1.54M$137.0K-----
Current Assets$55.65M$63.21M$71.71M$80.55M$87.96M$304.6K$602.5K$717.5K$860.5K$1.11M
Total Assets$57.74M$64.72M$72.11M$81.00M$87.98M$86.56M$86.85M$86.97M$87.11M$87.35M
Current Liabilities$8.43M$4.13M$3.40M$4.03M$194.0K-----
Long-term Debt----------
Total Liabilities$15.03M$7.37M$11.37M$27.45M$34.56M$6.16M$5.97M$859.4K$792.5K$2.4K
Stockholders' Equity$42.71M$57.35M$60.74M$53.54M$53.41M($5.86M)($5.37M)$5.00M$5.00M$5.00M
Retained Earnings($31.66M)($16.43M)($12.40M)($19.00M)($18.47M)-----

Cash Flow

Line itemQ3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21Q1 '21Q4 '20Q3 '20Q2 '20
Operating Cash Flow--($8.29M)---($91.5K)---
Investing Cash Flow--($360.0K)-------
Financing Cash Flow--($80.0K)-------
CapEx--$360.0K-------
Free Cash Flow--($8.65M)-------

Ratios

MetricQ3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21Q1 '21Q4 '20Q3 '20Q2 '20
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income---1.31-------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-26.4%-6.2%9.1%--9.3%-0.6%-1.4%--0.6%-0.1%
Return on equity-35.7%-7.0%10.9%--15.3%8.3%22.3%--9.7%-1.4%
Return on invested capital----------
Liquidity
Current ratio6.6015.3221.1119.97453.38-----
Quick ratio6.6015.3221.1119.97453.38-----
Cash ratio6.3715.0320.6319.53439.69-----
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage-3026.3x----35.6x-----
Equity multiplier1.351.131.191.511.65-14.78-16.1817.3917.4217.47
Liabilities / Assets0.260.110.160.340.390.070.070.010.010.00
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-131.0%-740.4%-52225.2%--963.3%-1219.0%----
Net income growth (YoY)-86.4%-724.6%---1585.0%-589.4%-6968.8%---
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-20.0%--970.9%968.3%-----

Peer comparison

Same SIC group: Biological Products, (No Diagnostic Substances)

CompanyRevenue (last FY)Net marginROE
TWST---16.4%
AMGN$36.75B21.0%89.1%
RXRX$74.68M-863.4%-57.0%
MRNA$1.94B-145.2%-32.6%
DNA$170.16M-183.8%-61.5%

Comparing Renovacor against the 5 most active filers in the same SIC group.